Obesity in bipolar disorder: An overview

Current Psychiatry Reports

Volumn 14, Issue 6, 2012, Pages 650-658

  McElroy, Susan L ^a,b   Keck Jr , Paul E ^a,b  

^a LINDNER CENTER OF HOPE   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Bariatric surgery; BD; Binge eating disorder; Bipolar disorder; Co occurrence; Comorbid eating disorders; Diet; Exercise; Metabolic syndrome; Obesity; Pharmacotherapy; Psychiatry; Weight management

Indexed keywords

AMANTADINE; AMFEBUTAMONE; AMFEBUTAMONE PLUS ZONISAMIDE; AMFEPRAMONE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZPHETAMINE; BROMOCRIPTINE; CLOZAPINE; DOPAMINE RECEPTOR STIMULATING AGENT; FLUOXETINE; LAMOTRIGINE; LITHIUM; METFORMIN; MODAFINIL; MOOD STABILIZER; NALTREXONE; NEUROLEPTIC AGENT; OLANZAPINE; PHENDIMETRAZINE; PHENTERMINE; PHENTERMINE PLUS TOPIRAMATE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; TETRAHYDROLIPSTATIN; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; ZONISAMIDE;

ABDOMINAL OBESITY; ANXIETY DISORDER; BARIATRIC SURGERY; BINGE EATING DISORDER; BIPOLAR DISORDER; BIPOLAR I DISORDER; BIPOLAR MANIA; COMORBIDITY; DIET THERAPY; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DRUG EFFICACY; EATING DISORDER; HUMAN; KINESIOTHERAPY; LIFESTYLE MODIFICATION; MENTAL DISEASE; METABOLIC SYNDROME X; NONHUMAN; OBESITY; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; WEIGHT GAIN; WEIGHT REDUCTION;

BIPOLAR DISORDER; HUMANS; OBESITY;

EID: 84870840516     PISSN: 15233812     EISSN: 15351645     Source Type: Journal    
DOI: 10.1007/s11920-012-0313-8     Document Type: Review

References (99)

1. McElroy SL, Kotwal R, Malhotra S, et al. Are mood disorders and obesity related? A review for the mental health professional. J Clin Psychiatry. 2004;65:634-51.
2. McElroy SL. Obesity in patients with severe mental illness: Overview and management. J Clin Psychiatry. 2009;70 Suppl 3:12-21.
3. De Hert M, Correll CU, Bobes J, et al. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry. 2011;10:52-77.
4. Taylor VH, McIntyre RS, Remington G, et al. Beyond pharmacotherapy: Understanding the links between obesity and chronic mental illness. Can J Psychiatry. 2012;57:5-12.
5. McIntyre RS, Alsuwaidan M, Goldstein BI, et al. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid metabolic disorders. Ann Clin Psychiatry. 2012;24:69-81.
6. Bray GA. Obesity: The disease. J Med Chem. 2006;49:4001-7. (Pubitemid 44036645)
7. National Institutes of Health. National Heart, Lung and Blood Institute: Clinical Guidelines on the Identification, Evaluation and Treatment of Overweight in Adults: The Evidence Report. National Institutes of Health, Bethesda, MD, 1998.
8. World Health Organization: Obesity and overweight. Fact sheet N° 311. Available via http://www.who.int/mediacentre/factsheets/fs311/en/index.html. Accessed 12 Apr 2012.
9. de Koning L, Merchant AT, Pogue J, et al. Waist circumference and waist-to-hip ratio as predictors of cardiovascular events: Metaregression analysis of prospective studies. Eur Heart J. 2007;28:850-6. (Pubitemid 47343598)
10. de Vegt F, Dekker JM, Jager A, et al. Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: The Hoorn Study. JAMA. 2001;285:2109-13. (Pubitemid 32367828)
11. Berrington de Gonzalez A, Hartge P, Cerhan JR, et al. Body-mass index and mortality among 146 million white adults. N Engl J Med. 2010;363:2211-9.
12. Lee EB. Obesity, leptin, and Alzheimer's disease. Ann N Y Acad Sci. 2011;1243:15-29.
13. Guize L, Pannier B, Thomas F, et al. Recent advances in metabolic syndrome and cardiovascular disease. Arch Cardiovasc Dis. 2008;101:577-83.
14. Finucane MM, Stevens GA, Cowan MJ, et al. National, regional, and global trends in body-mass index since 1980: Systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet. 2011;377:557-67.
15. Ogden CL, Yanovski SZ, Carroll MD, et al. The epidemiology of obesity. Gastroenterology. 2007;132:2087-102. (Pubitemid 46693751)
16. Flegal KM, Carroll MD, Kit BK, et al. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA. 2012;307:491-7.
17. Sturm R. Increases in morbid obesity in the USA: 2000-2005. Public Health. 2007;121:492-6. (Pubitemid 46895458)
18. Walls HL, Magliano DJ, McNeil JJ, et al. Predictors of increasing waist circumference in an Australian population. Public Health Nutr. 2011;14:870-81.
19. McAllister EJ, Dhurandhar NV, Keith SW, et al. Ten putative contributors to the obesity epidemic. Crit Rev Food Sci Nutr. 2009;49:868-913.
20. Keck PE, McElroy SL. Bipolar disorder, obesity, and pharmacotherapy- associated weight gain. J Clin Psychiatry. 2003;64:1426-35. (Pubitemid 41270100)
21. Sicras A, Rejas J, Navarro R, et al. Metabolic syndrome in bipolar disorder: A cross-sectional assessment of a Health Management Organization database. Bipolar Disord. 2008;10:607-16. (Pubitemid 352003828)
22. Weber NS, Fisher JA, Cowan DN, et al. Psychiatric and general medical conditions comorbid with bipolar disorder in the National Hospital Discharge Survey. Psychiatr Serv. 2011;62:1152-8.
23. Goldstein BI, Birmaher B, Axelson DA, et al. Preliminary findings regarding overweight and obesity in pediatric bipolar disorder. J Clin Psychiatry. 2008;69:1953-9.
24. Kim B, Kim SJ, Son JI, et al. Weight change in the acute treatment of bipolar I disorder: a naturalistic observational study of psychiatric inpatients. J Affect Disord. 2008;105:45-52. (Pubitemid 350236344)
25. Maina G, Salvi V, Vitalucci A, et al. Prevalence and correlates of overweight in drug-naive patients with bipolar disorder. J Affect Disord. 2008;110:149-55.
26. Alciati A, Gesuele F, Rizzi A, et al. Childhood parental loss and bipolar spectrum in obese bariatric surgery candidates. Int J Psychiatry Med. 2011;41:155-71.
27. McIntyre RS, Konarski JZ, Wilkins K, et al. Obesity in bipolar disorder and major depressive disorder: Results from a national community health survey on mental health and well-being. Can J Psychiatry. 2006;51:274-80. (Pubitemid 43764709)
28. McIntyre RS, McElroy SL, Konarski JZ, et al. Substance use disorders and overweight/obesity in bipolar I disorder: Preliminary evidence for competing addictions. J Clin Psychiatry. 2007;68:1352-7. (Pubitemid 47524514)
29. Simon GE, Von Korff M, Saunders K, et al. Association between obesity and psychiatric disorders in the US adult population. Arch Gen Psychiatry. 2006;63:824-30.
30. Goldstein BI, Liu SM, Zivkovic N, et al. The burden of obesity among adults with bipolar disorder in the United States. Bipolar Disord. 2011;13:387-95.
31. Petry NM, Barry D, Pietrzak RH, et al. Overweight and obesity are associated with psychiatric disorders: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. Psychosom Med. 2008;70:288-97. (Pubitemid 351543491)
32. Osby U, Brandt L, Correia N, et al. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry. 2001;58:844-50. (Pubitemid 32979302)
33. Brietzke E, Kapczinski F, Grassi-Oliveira R, et al. Insulin dysfunction and allostatic load in bipolar disorder. Expert Rev Neurother. 2011;11:1017-28.
34. Kilbourne AM, Cornelius JR, Han X, et al. Burden of general medical conditions among individuals with bipolar disorder. Bipolar Disord. 2004;6:368-73. (Pubitemid 39345287)
35. Fagiolini A, Kupfer DJ, Rucci P, et al. Suicide attempts and ideation in patients with bipolar I disorder. J Clin Psychiatry. 2004;65:509-14.
36. Yim CY, Soczynska JK, Kennedy SH, et al. The effect of overweight/obesity on cognitive function in euthymic individuals with bipolar disorder. Eur Psychiatry. 2012;27:223-8.
37. Fagiolini A, Kupfer DJ, Houck PR, et al. Obesity as a correlate of outcome in patients with bipolar I disorder. Am J Psychiatry. 2003;160:112-7. (Pubitemid 36042434)
38. Bond DJ, Kunz M, Torres IJ, et al. The association of weight gain with mood symptoms and functional outcomes following a first manic episode: prospective 12-month data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM). Bipolar Disord. 2010;12:616-26.
39. Goldstein BI, Kemp DE, Soczynska JK, et al. Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: A systematic review of the literature. J Clin Psychiatry. 2009;70:1078-90.
40. Bond DJ, Lang DJ, Noronha MM, et al. The association of elevated body mass index with reduced brain volumes in first-episode mania. Biol Psychiatry. 2011;70:381-7.
41. Torrent C, Amann B, Sanchez-Moreno J, et al. Weight gain in bipolar disorder: Pharmacological treatment as a contributing factor. Acta Psychiatr Scand. 2008;118:4-18. (Pubitemid 351832022)
42. Lipkovich I, Citrome L, Perlis R, et al. Early predictors of substantial weight gain in bipolar patients treated with olanzapine. J Clin Psychopharmacol. 2006;26:316-20. (Pubitemid 43804625)
43. McElroy SL, Frye MA, Suppes T, et al. Correlates of overweight and obesity in 644 patients with bipolar disorder. J Clin Psychiatry. 2002;63:207-13. (Pubitemid 34407079)
44. McElroy SL, Frye MA, Hellemann G, et al. Prevalence and correlates of eating disorders in 875 patients with bipolar disorder. J Affect Disord. 2011;128:191-8.
45. Barry D, Pietrzak RH, Petry NM. Gender differences in associations between body mass index and DSM-IV mood and anxiety disorders: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. Ann Epidemiol. 2008;18:458-66.
46. Elmslie JL, Mann JI, Silverstone JT, et al. Determinants of overweight and obesity in patients with bipolar disorder. J Clin Psychiatry. 2001;62:486-91. (Pubitemid 32717891)
47. Fleet-Michaliszyn SB, Soreca I, Otto AD, et al. A prospective observational study of obesity, body composition, and insulin resistance in 18 women with bipolar disorder and 17 matched control subjects. J Clin Psychiatry. 2008;69:1892-900.
48. Delgado-Rico E, Rio-Valle JS, Gonzalez-Jimenez E, et al. BMI predicts emotion-driven impulsivity and cognitive inflexibility in adolescents with excess weight. Obesity (Silver Spring). 2012;20:1604-10.
49. Fernandes BS, Gama CS, Cereser KM, et al. Brain-derived neurotrophic factor as a state-marker of mood episodes in bipolar disorders: a systematic review and meta-regression analysis. J Psychiatr Res. 2011;45:995-1004.
50. Cordeira J, Rios M. Weighing in the role of BDNF in the central control of eating behavior. Mol Neurobiol. 2011;44:441-8.
51. Anand A, Barkay G, Dzemidzic M, et al. Striatal dopamine transporter availability in unmedicated bipolar disorder. Bipolar Disord. 2011;13:406-13.
52. Carlson PJ, Merlock MC, Suppes T. Adjunctive stimulant use in patients with bipolar disorder: treatment of residual depression and sedation. Bipolar Disord. 2004;6:416-20. (Pubitemid 39345293)
53. Goldberg JF, Burdick KE, Endick CJ. Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. Am J Psychiatry. 2004;161:564-6. (Pubitemid 38326114)
54. Zarate Jr CA, Payne JL, Singh J, et al. Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biol Psychiatry. 2004;56:54-60. (Pubitemid 38813406)
55. Frye MA, Grunze H, Suppes T, et al. A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression. Am J Psychiatry. 2007;164:1242-9. (Pubitemid 47292414)
56. Calabrese JR, Ketter TA, Youakim JM, et al. Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder: a randomized, multicenter, double-blind, placebo-controlled, proof-of-concept study. J Clin Psychiatry. 2010;71:1363-70.
57. Finger BC, Dinan TG, Cryan JF. High-fat diet selectively protects against the effects of chronic social stress in the mouse. Neuroscience. 2011;192:351-60.
58. Yamada N, Katsuura G, Ochi Y, et al. Impaired CNS leptin action is implicated in depression associated with obesity. Endocrinology. 2011;152:2634-43.
59. Black DW, Goldstein RB, Mason EE, et al. Depression and other mental disorders in the relatives of morbidly obese patients. J Affect Disord. 1992;25:91-5.
60. Grucza RA, Krueger RF, Racette SB, et al. The emerging link between alcoholism risk and obesity in the United States. Arch Gen Psychiatry. 2010;67:1301-8.
61. Heber D, Carpenter CL. Addictive genes and the relationship to obesity and inflammation. Mol Neurobiol. 2011;44:160-5.
62. De Hert M, Cohen D, Bobes J, et al. Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. World Psychiatry. 2011;10:138-51.
63. Ahmed AT, Blair TR, McIntyre RS. Surgical treatment of morbid obesity among patients with bipolar disorder: A research agenda. Adv Ther. 2011;28:389-400.
64. Mark AL. Dietary therapy for obesity: An emperor with no clothes. Hypertension. 2008;51:1426-34.
65. Rejeski WJ, Ip EH, Bertoni AG, et al. Lifestyle change and mobility in obese adults with type 2 diabetes. N Engl J Med. 2012;366:1209-17.
66. Alvarez-Jimenez M, Hetrick SE, Gonzalez-Blanch C, et al. Nonpharmacological management of antipsychotic-induced weight gain: Systematic review and meta-analysis of randomised controlled trials. Br J Psychiatry. 2008;193:101-7.
67. Faulkner G, Cohn T, Remington G. Interventions to reduce weight gain in schizophrenia. Cochrane Database Syst Rev. 2007: CD005148.
68. Gillhoff K, Gaab J, Emini L, et al. Effects of a multimodal lifestyle intervention on body mass index in patients with bipolar disorder: a randomized controlled trial. Prim Care Companion J Clin Psychiatry. 2010;12:pii.
69. Sarris J, Mischoulon D, Schweitzer I. Adjunctive nutraceuticals with standard pharmacotherapies in bipolar disorder: A systematic review of clinical trials. Bipolar Disord. 2011;13:454-65.
70. Kwak SM, Myung SK, Lee YJ, et al. Efficacy of omega-3 fatty acid supplements (eicosapentaenoic acid and docosahexaenoic acid) in the secondary prevention of cardiovascular disease: A meta-analysis of randomized, double-blind, placebo-controlled trials. Arch Intern Med. 2012;172:686-94.
71. Milaneschi Y, Bandinelli S, Penninx BW, et al. Depressive symptoms and inflammation increase in a prospective study of older adults: A protective effect of a healthy (Mediterranean-style) diet. Mol Psychiatry. 2011;16:589-90.
72. Elmslie JL, Porter RJ, Joyce PR, et al. Carnitine does not improve weight loss outcomes in valproate-treated bipolar patients consuming an energy-restricted, low-fat diet. Bipolar Disord. 2006;8:503-7. (Pubitemid 44560225)
73. Malik VS, Hu FB. Sweeteners and risk of obesity and type 2 diabetes: The role of sugar-sweetened beverages. Curr Diab Rep. 2012;12:195-203.
74. Richardson CR, Faulkner G, McDevitt J, et al. Integrating physical activity into mental health services for persons with serious mental illness. Psychiatr Serv. 2005;56:324-31. (Pubitemid 40333566)
75. Alsuwaidan MT, Kucyi A, Law CW, et al. Exercise and bipolar disorder: A review of neurobiological mediators. Neuromolecular Med. 2009;11:328-36.
76. Sylvia LG, Ametrano RM, Nierenberg AA. Exercise treatment for bipolar disorder: potential mechanisms of action mediated through increased neurogenesis and decreased allostatic load. Psychother Psychosom. 2010;79:87-96.
77. Poulin MJ, Chaput JP, Simard V, et al. Management of antipsychotic- induced weight gain: prospective naturalistic study of the effectiveness of a supervised exercise programme. Aust N Z J Psychiatry. 2007;41:980-9. (Pubitemid 350120827)
78. Wright K, Armstrong T, Taylor A, et al. 'It's a double edged sword': A qualitative analysis of the experiences of exercise amongst people with bipolar disorder. J Affect Disord. 2012;136:634-42.
79. Maayan L, Vakhrusheva J, Correll CU. Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: A systematic review and meta-analysis. Neuropsychopharmacology. 2010;35:1520-30.
80. Agarwal SM, Behere RV, Venkatasubramanian G, et al. A case of successful treatment of comorbid obesity and polycystic ovarian disease with add-on metformin in bipolar disorder. Prim Care Companion CNS Disord. 2011;13:pii.
81. McElroy SL, Guerdjikova AI, Mori N, et al. Pharmacolgical management of binge eating disorder: Current and emerging treatment options. Ther Clin Risk Manag. 2012;8:219-41.
82. Tchoukhine E, Takala P, Hakko H, et al. Orlistat in clozapine- or olanzapine-treated patients with overweight or obesity: A 16-week open-label extension phase and both phases of a randomized controlled trial. J Clin Psychiatry. 2011;72:326-30.
83. Ioannides-Demos LL, Piccenna L, McNeil JJ. Pharmacotherapies for obesity: Past, current, and future therapies. J Obes. 2011;2011:179674.
84. Merideth CH. A single-center, double-blind, placebo-controlled evaluation of lamotrigine in the treatment of obesity in adults. J Clin Psychiatry. 2006;67:258-62. (Pubitemid 43357472)
85. Kushner SF, Khan A, Lane R, et al. Topiramate monotherapy in the management of acute mania: Results of four double-blind placebo-controlled trials. Bipolar Disord. 2006;8:15-27. (Pubitemid 43356017)
86. Roy Chengappa KN, Schwarzman LK, Hulihan JF, et al. Adjunctive topiramate therapy in patients receiving a mood stabilizer for bipolar I disorder: A randomized, placebo-controlled trial. J Clin Psychiatry. 2006;67:1698-706. (Pubitemid 44955149)
87. Roy Chengappa K, Kupfer DJ, Parepally H, et al. A placebo-controlled, random-assignment, parallel-group pilot study of adjunctive topiramate for patients with schizoaffective disorder, bipolar type. Bipolar Disord. 2007;9:609-17. (Pubitemid 47365629)
88. McIntyre RS, Mancini DA, McCann S, et al. Topiramate versus bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: A preliminary single-blind study. Bipolar Disord. 2002;4:207-13. (Pubitemid 34591247)
89. McElroy SL, Winstanley E, Mori N, et al. A randomized, placebo-controlled study of zonisamide to prevent olanzapine-associated weight gain. J Clin Psychopharmacol. 2012;32:165-72.
90. Bowden CL, Calabrese JR, Ketter TA, et al. Impact of lamotrigine and lithium on weight in obese and nonobese patients with bipolar I disorder. Am J Psychiatry. 2006;163:1199-201. (Pubitemid 44464447)
91. Bray GA, Greenway FL. Pharmacological treatment of the overweight patient. Pharmacol Rev. 2007;59:151-84. (Pubitemid 46855438)
92. Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry. 2003;60:1079-88. (Pubitemid 37429647)
93. Cincotta AH, Meier AH. Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects. Diabetes Care. 1996;19:667-70. (Pubitemid 26182986)
94. Henderson DC, Freudenreich O, Borba CP, et al. Effects ofmodafinil on weight, glucose and lipid metabolism in clozapine-treated patients with schizophrenia. Schizophr Res. 2011;130:53-6.
95. Via MA, Chandra H, Araki T, et al. Bromocriptine approved as the first medication to target dopamine activity to improve glycemic control in patients with type 2 diabetes. Diabetes Metab Syndr Obes. 2010;3:43-8.
96. Graham KA, Gu H, Lieberman JA, et al. Double-blind, placebo-controlled investigation of amantadine for weight loss in subjects who gainedweightwith olanzapine. Am J Psychiatry. 2005;162:1744-6. (Pubitemid 41318248)
97. Deberdt W, Winokur A, Cavazzoni PA, et al. Amantadine for weight gain associated with olanzapine treatment. Eur Neuropsychopharmacol. 2005;15:13-21. (Pubitemid 39574395)
98. Semanscin-Doerr DA, Windover A, Ashton K, et al. Mood disorders in laparoscopic sleeve gastrectomy patients: Does it affect early weight loss? Surg Obes Relat Dis. 2010;6:191-6.
99. Steinmann WC, Suttmoeller K, Chitima-Matsiga R, et al. Bariatric surgery: 1-year weight loss outcomes in patients with bipolar and other psychiatric disorders. Obes Surg. 2011;21:1323-9.